SCHEDULE: Roivant Boosts Immunovant Stake to 55.9% in $350M Offering

Roivant Sciences Ltd. increased its beneficial ownership in Immunovant, Inc. to 55.9% by acquiring 16.67 million shares in a recent public offering.

Summary

• Roivant Sciences Ltd. (Reporting Person) acquired an additional 16,666,666 shares of Immunovant, Inc. Common Stock.
• The acquisition occurred in an underwritten public offering that closed on December 12, 2025.
• The price per share of Common Stock in the offering was $21.00.
• Following this transaction, Roivant beneficially owns 113,327,007 shares, representing 55.9% of Immunovant's Common Stock.
• This ownership includes 10,000 Series A Preferred Stock shares convertible into Common Stock.
• The total shares of Common Stock issued and outstanding as of December 12, 2025, for calculation purposes, is 202,678,277.
• The purpose of the purchase was to provide further capital to Immunovant for the advancement of its development pipeline, working capital, and other general corporate purposes, as well as to increase Roivant's ownership interest.

Sentiment

Score: 8

Explanation: The filing indicates strong financial support and confidence from a major shareholder, Roivant, through a significant capital injection and increased ownership. This provides Immunovant with resources for its development pipeline and signals long-term commitment, which is generally positive for the company's stability and growth prospects, despite the inherent dilution from the offering.

Positives

• Immunovant received significant capital, approximately $350 million, from its largest shareholder, Roivant, to fund its development pipeline and general corporate purposes.
• Roivant's increased stake to 55.9% demonstrates strong confidence in Immunovant's future prospects and strategic direction.
• Roivant indicated a willingness to provide additional financing in the future, potentially through equity, debt, or loans, which could support future business development.

Negatives

• The public offering likely resulted in dilution for existing shareholders not participating in the offering.

Future Outlook

Roivant, as Immunovant's largest shareholder, may provide additional financing in the future through equity, debt, or loans, potentially supporting business development transactions or financing commitments.

Management Comments

• Roivant purchased an aggregate of 16,666,666 shares of Common Stock in the Offering to provide further capital to the Issuer for the advancement of the Issuer's development pipeline, working capital and other general corporate purposes, as well as to increase its ownership interest in the Issuer following the Offering.
• As the Issuer's largest shareholder, Roivant may provide additional financing to the Issuer from time to time in the form of an investment in equity or debt securities of the Issuer or loans, including in connection with business development transactions or financing commitments in relation thereto.

Industry Context

This capital infusion from a major shareholder like Roivant is common in the biotechnology sector, where companies often require substantial funding to advance their drug development pipelines. Roivant's continued investment signals confidence in Immunovant's specific pipeline and strategic direction, potentially differentiating it from competitors facing funding challenges.

Related Party Transactions

• Roivant Sciences Ltd., as Immunovant's largest shareholder, acquired 16,666,666 shares in a public offering to provide further capital to Immunovant.

Stakeholder Impact

• Shareholders: Existing shareholders not participating in the offering experienced dilution. Shareholders may benefit from increased capital for pipeline development and Roivant's continued support.
• Company (Immunovant): Received significant capital to fund its development pipeline, working capital, and general corporate purposes.
• Employees: Potential for increased stability and continued investment in company operations.

Next Steps

• Immunovant will utilize the capital for the advancement of its development pipeline, working capital, and other general corporate purposes.
• Roivant may provide additional financing to Immunovant in the future.

Key Dates

Recommendation

The filing indicates strong insider confidence and a significant capital injection from Roivant, Immunovant's largest shareholder, which is a positive signal for the company's financial stability and pipeline advancement. However, the public offering itself implies dilution for non-participating shareholders. While the long-term outlook appears strengthened by this commitment, a 'hold' recommendation is appropriate to observe how the new capital is deployed and its impact on clinical milestones and financial performance before a stronger 'buy' signal, especially considering the inherent risks in biotech development.

Keywords

Immunovant, Roivant Sciences, Schedule 13D, Equity Offering, Share Acquisition, Biotechnology, Pharmaceuticals, Investment, Beneficial Ownership, Capital Raise